STADA acquires Sanofi’s consumer healthcare brands & strikes distribution agreement
Ten post jest także dostępny w języku: polski
STADA is embarking on a significant expansion of its European Consumer Healthcare portfolio. The company agreed to acquire from Sanofi portfolio of 16 well-established local and regional consumer healthcare brands in 13 European countries, including Poland. The transaction is scheduled to close in Q3 2021, subject to the approval of relevant regulatory authorities and other customary closing conditions. Shortly after, the companies also entered into a distribution agreement, covering 20 countries.
The asset-purchase agreement includes registrations, trademarks and related commercial rights to the 16 brands, including, among others, Mitosyl ointment and wipes for daily care of sensitive areas and protection against diaper irritation; Silomat dry-cough remedies; Frubiase nutritional supplements for athletes; Modafen cold and flu relief tablets; and the Viscontour allergen-free skincare range. Manufacturing assets or employees were not included in the transaction.
The company is also planning to explore synergy potential, by means of transferring manufacturing of certain brands into the group’s existing supply-chain network. The bulk of the annual turnover of the acquired portfolio is now achieved in five European countries, namely France, Germany, Spain, Italy and Poland. Half of these sales are generated by cough and cold brands, while derma brands contribute around one third,
The transaction follows last year’s acquisition of consumer healthcare brands from GSK 15 across more than 40 countries and multiple therapeutic areas. STADA also recently acquired Czech healthcare company Walmark.
STADA and Sanofi have also recently entered into a distribution agreement, whereby Sanofi will distribute its products through STADA in 20 countries across Europe from November 2021. These include the Nordic countries, the Netherlands, Ireland, Bulgaria and the Baltic States, as well as Balkan and Adriatic countries. The agreement covers some 50 consumer healthcare brands currently marketed by Sanofi in these territories, including Allegra, Bisolvon, Dulcolax and Essentiale Forte N.
A detailed report on sales of OTC products, including dietary supplements, is available here: “OTC market in Poland 2021“